IQVIA Holdings Inc. $IQV Position Boosted by Aviva PLC

Aviva PLC boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.1% during the 2nd quarter, Holdings Channel reports. The fund owned 131,882 shares of the medical research company’s stock after acquiring an additional 5,189 shares during the quarter. Aviva PLC’s holdings in IQVIA were worth $20,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of IQV. Everpar Advisors LLC increased its holdings in shares of IQVIA by 4.6% during the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 62 shares during the period. Private Trust Co. NA grew its position in IQVIA by 12.5% in the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after buying an additional 67 shares in the last quarter. Ballentine Partners LLC increased its stake in IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after buying an additional 69 shares during the period. Independent Advisor Alliance raised its position in shares of IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after buying an additional 72 shares in the last quarter. Finally, Nemes Rush Group LLC lifted its stake in shares of IQVIA by 15.0% in the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock worth $109,000 after acquiring an additional 81 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $213.39 on Tuesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $225.00. The firm’s 50 day simple moving average is $199.83 and its 200-day simple moving average is $176.94. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The company has a market cap of $36.34 billion, a P/E ratio of 29.27, a price-to-earnings-growth ratio of 2.35 and a beta of 1.34.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the business posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on IQV shares. TD Cowen cut IQVIA from a “buy” rating to a “hold” rating and boosted their target price for the stock from $206.00 to $215.00 in a report on Monday, November 3rd. Stifel Nicolaus lifted their price target on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Truist Financial restated a “buy” rating and issued a $265.00 price objective (up previously from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. Redburn Partners set a $214.00 target price on IQVIA in a report on Wednesday, September 3rd. Finally, Mizuho boosted their price target on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $239.94.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.